Proceedings: Role of immunocompetence in localized BCG suppression of tumour growth. by Pimm, M. V. & Hopper, D. G.
ABSTRACTS OF MEMBERS PAPERS 241
discussed in relation to the occurrence and
expression of cross-reacting embryonic anti-
gens associated with the cell surface of these
rat tumours.
B AND T CELLS IN CANINE LYMPHO-
SARCOMA. D. E. ONIoNs, Department of
Clinical Veterinary Medicine, University of
Cambridge.
Canine multicentric lymphosarcoma is a
common spontaneous neoplasm of dogs.
Canine lymphoma cells, like normal canine
lymphocytes, may be divided into two classes,
T and B, based on the spontaneous rosette
formation between canine T cells and human
erythrocytes, and the presence of a receptor
for (human) complement on the surface of B
cells.
The presence of an Fc receptor on canine
lymphocytes appears to be an unreliable
marker for B cells as many complement
receptor lymphocytes (EACL) lack a
detectable Fc receptor for using a rosetting
technique with antibody coated eryth-
rocytes.
SCANNING ELECTRON MICROS-
COPY OF K CELL ACTIVITY ON RED
CELL MONOLAYERS. A. E. WILLIAMS,
Western General Hospital, Edinburgh, J. R.
INGLIS, W. J. Penhale, A. FARMER and W. J.
IRVINE, Department of Therapeutics, Uni-
versity of Edinburgh.
K cell activity against syngeneic cells
(De Landazuriet et al., Cell Immunol. 1974,
14, 193) and defects in K cell activity in
cancer patients (Wisloff et al., Scand. J.
Immunol., 1973, 2, 325) have been demon-
strated. However, the identity of the K cell
is still uncertain and conflicting evidence
supports B lymphocytes, monocytes, macro-
phages and other leucocytes.
We have used the SEM to examine the
interaction between human leucocytes
(separated in Ficoll-Triosil and pre-incubated
on glass) and antibody coated sheep erythro-
cyte monolayers (Kennedy and Axelrad,
Immunology, 1971, 20, 253). Only a small
proportion of the leucocyte suspension
adhered to the monolayer and the non-
adherent cells lacked antibody dependent
cytotoxic activity. Three morphologically
distinct cell types were associated with areas
of lysis in the erythrocyte monolayer within
4 h and correlation with light microscopy
suggested that they were macrophages,
granulocytes and lymphoid cells. Surface
changes in the erythrocytes during contact
with K cells indicate that mechanical factors
may be involved in cell lysis in this system.
THERAPY OF METHYL CHOLAN-
THRENE INDUCED CBA MOUSE TU-
MOURS WITH CORYNEBACTERIUM
PARVUM AND IRRADIATED TU-
MOUR CELLS. R. BOMFORD, Depart-
ment of Experimental Immunobiology,
WellcomeResearchLaboratories,Beckenham.
Mice were injected subcutaneously with
2 x 104 tumour cells and 2 days later given
C. parvum, irradiated tumour cells, or both
admixed, into the footpad. Tumour growth
was unaffected by C. parvum or tumour cells
alone, but was suppressed by appropriate
mixtures. The conditions for successful
therapy were: 1. sufficient tumour cells
(> 5 x 104); 2. sufficient, but not excessive,
C. parvum (optimally between about 5 to
20 [kg, increasing with the dose of tumour
cells); 3. the same tumour cells in the tumour
challenge and treatment mixture; other
MCA tumour cells were ineffective; 4. mice
with an intact T cell system; tumour growth
was not suppressed in T cell depleted mice.
The results suggest that the therapeutic
effect depends on the potentiation by C.
parvum of a T cell dependent component of
the immune response to TSTAs.
ROLE OF IMMUNOCOMPETENCE IN
LOCALIZED BCG SUPPRESSION OF
TUMOUR GROWTH. M. V. PIMM and
D. G. Hopper, Cancer Research Campaign
Laboratories, University ofNottingham.
Admixture ofBCG organisms with cells of
syngeneically transplanted rat tumours pre-
vents their development and this leads to
immunologically specific rejection of tumour
deposits at distant sites. Immunosuppres-
sion by whole body irradiation did not pre-
vent suppression ofgrowth from mixed BCG:
tumour cell inocula but did abrogate the
concomitant rejection of distant challenge
inocula. Tumour suppression at the site of
BCG was, however, prevented by macrophage
depletion of the host by silica treatment.
These observations suggest that local BCG
suppression of tumour does not require
lymphocyte mediated immune responses and
probably depends on less specific macrophage
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reactions. This is further supported by
comparable studies in athymic (" nude ")
mice, where admixture with BCG prevented
subcutaneous development of rat tumour cell
inocula.
The implication from these findings is that
localized BCG treatment may still be applic-
able clinically, even when immunosuppression
has resulted from chemotherapy or radio-
therapy.
TUMOUR ANTIGEN IN HUMAN CAN-
CER PATIENTS' SERA. J. G. BOWEN,
Cancer Research Campaign Laboratories,
University of Nottingham.
Previous studies (Baldwin, Bowen and
Price, Br. J. Cancer, 1973, 28, 16) have
shown that tumour specific antigen can be
isolated from the serum of rats bearing a
transplanted aminoazo dye-induced hepa-
toma. The present study was undertaken to
determine if the sera of human bladder
cancer patients contained a tumour specific
antigen. Sera were fractionated by Sepha-
dex G-150 gel chromatography and material
with a molecular weight less than 150,000
Daltons examined for the presence of tumour
specific antigen by the leucocyte migration
inhibition test using leucocytes from bladder
cancer patients, other cancer patients and
non-cancer hospital patients. Antigen could
be detected in the sera of patients bearing
turnour in situ and those within one month of
tumour elimination. Patients tumour free
for longer than 3-4 years lacked reactivity
against the tumour bearer serum fraction.
CELL MEDIATED CYTOTOXICITY
(CMC) IN PATIENTS WITH ACUTE
MYELOBLASTIC LEUKAEMIA RE-
CEIVING IMMUNOTHERAPY. G. M.
TAYLOR, R. HARRIS and C. B. FREEMAN,
Department of Medical Genetics, St Mary's
Hospital, Manchester.
The effect of immunotherapy with allo-
geneic leukaemic blasts in patients with
acute myeloid leukaemia (AML) was assessed
by stimulating lymphocytes from these
patients when in remission and also lympho-
cytes from normal donors with immuno-
therapy blasts (I blasts), Burkitt's lymphoma
(RAJI) cells and normal lymphoblastoid
cells (LCL). After 6 days in culture,
stimulated lymphocytes were cross-tested for
cell mediated cytoxicity (CMC) against 51Cr
-labelled target cells of the same origin as
those used to stimulate the lymphocytes.
Patients on immunotherapy, and stimulated
invitrowithIblasts invariably showed ahigher
level of line directed CMC compared with
normals whereas cross tests of the same
lymphocytes against RAJI and LCL cells
revealed lower, though reproducible, cytoto-
xicity. RAJI generally failed to produce
cytotoxicity either in patients or normals,
whilst LCL induced cytotoxicity in both
sources oflymphocytes, withsome evidence of
cross-reactivity. Immunotherapy patients
seem topossessa pool oflymphocytes capable
of restimulation in vitro to give high levelsof
CMC,apropertywhichcouldbeusefulforevalu-
ating the response to immunotherapy ofAML
patients and which could aid the search for
tumour associated antigens on autochthonous
blasts. Moreover, CMC response is direct
evidence that the measures being used at
present to induce cell mediated immunity
in these patients do in fact work and may
be of value in selecting cells for use in
immunotherapy.
ACTIVE IMMUNOTHERAPY IN
ACUTE MYELOID LEUKAEMIA. C. B
FREEMAN, G. M. TAYLOR and R. HARRIS,
St Mary's Hospital, Manchester, and C. G.
GEARY, J. E. MACIVER and I. W. DELAMORE,
Manchester Royal Infirmary.
The duration of first remission in a small
group (7) of acute myeloid leukaemia (AML)
patients maintained with irradiated allo-
geneic leukaemia cells and BCG, after initial
consolidation chemotherapy, was similar to
that achieved in comparable trials using
conventional chemotherapy (Freeman et al.,
Br. med. J., 1973, iv, 571). In a second series
of 20 patients in the MRC 6th AML Trial, to
whom the same immunotherapy was given
but without prior consolidation chemo-
therapy, the median duration of first re-
mission was considerably shorter.
Compared with patients receiving other
therapeutic protocols, there was a remarkably
high reinduction rate following relapse in
both series of patients maintained with
immunotherapy alone (second remissions in
group 1: 5/6, group 2: 12/18 with four third
remissions) and the overall survival figures
are very encouraging (group 1: 4/7 alive,
current mean survival 115 weeks, group 2:
13/20, current mean survival 50 weeks).